Answers are grounded in this paper and cite their sources.
Background: Melasma is a chronic relapsing pigmentary disorder in which ultraviolet and visible-light exposure may contribute to melanogenic signaling partly through oxidative stress. Objective: To describe exploratory clinical and tolerability observations during use of an HPR/retinol-based serum with tinted sunscreen containing Polypodium leucotomos extract. Methods: Thirty adults with melasma and Fitzpatrick skin types III–IV entered this single-arm prospective study. Serum was used nightly for 8 weeks and sunscreen daily for 12 weeks. Primary outcomes in the pre-enrollment protocol were Antera3D pigmentation and Mexameter melanin and erythema indices; physician-assessed severity and biophysical measures were secondary. Registration occurred after study completion. Results: Twenty-seven participants completed follow-up. At month 3, reported mean Antera3D pigmentation decreased from 46.63 to 44.57, Mexameter melanin index from 262.90 to 224.60, and mMASI from 7.80 to 6.32, corresponding to descriptive reductions of 4.4%, 14.6%, and 19.0% in the respective group means. Reported p values were exploratory. Increased Cutometer R0 indicated greater deformation under suction and did not establish improved firmness or elasticity. Ten participants reported local irritation; no moderate or severe adverse events or adverse-event-related discontinuations were reported. Conclusion: Modest within-cohort changes were observed. The uncontrolled concurrent-intervention design cannot establish efficacy, comparative effectiveness, synergy, or the contribution of either product or individual ingredient. These observations are hypothesis-generating; antioxidant-mediated efficacy cannot be inferred.
No takes yet. Share an insight, caveat, or question.
Seksunwiriya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: